Rie Kuroda1, Hiroshi Wakabayashi2, Raita Araki1, Anri Inaki3, Ryosei Nishimura1, Yasuhiro Ikawa1, Kenichi Yoshimura4, Toshinori Murayama5, Yasuhito Imai6, Tatsuyoshi Funasaka6, Taizo Wada1, Seigo Kinuya3. 1. Department of Paediatrics, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan. 2. Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan. wakabayashi@staff.kanazawa-u.ac.jp. 3. Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan. 4. Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, 734-8551, Japan. 5. Department of Clinical Development, Kanazawa University Hospital, 13-1 Takara-machi, Ishikawa, 920-8641, Japan. 6. Innovative Clinical Research Center, Kanazawa University Hospital, 13-1 Takara-machi, Ishikawa, 920-8641, Japan.
Abstract
PURPOSE: Paediatric high-risk neuroblastoma has poor prognosis despite modern multimodality therapy. This phase I/II study aimed to determine the safety, dose-limiting toxicity (DLT), and efficacy of high-dose 131I-meta-iodobenzylguanidine (131I-mIBG) therapy combined with single high-dose chemotherapy (HDC) and haematopoietic stem cell transplantation (HSCT) in high-risk neuroblastoma in Japan. METHODS: Patients received 666 MBq/kg of 131I-mIBG and single HDC and HSCT from autologous or allogeneic stem cell sources. The primary endpoint was DLT defined as adverse events associated with 131I-mIBG treatment posing a significant obstacle to subsequent HDC. The secondary endpoints were adverse events/reactions, haematopoietic stem cell engraftment and responses according to the Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) and 123I-mIBG scintigraphy. Response was evaluated after engraftment. RESULTS: We enrolled eight patients with high-risk neuroblastoma (six females; six newly diagnosed and two relapsed high-risk neuroblastoma; median age, 4 years; range, 1-10 years). Although all patients had adverse events/reactions after high-dose 131I-mIBG therapy, we found no DLT. Adverse events and reactions were observed in 100% and 25% patients during single HDC and 100% and 12.5% patients during HSCT, respectively. No Grade 4 complications except myelosuppression occurred during single HDC and HSCT. The response rate according to RECIST 1.1 was observed in 87.5% (7/8) in stable disease and 12.5% (1/8) were not evaluated. Scintigraphic response occurred in 62.5% (5/8) and 37.5% (3/8) patients in complete response and stable disease, respectively. CONCLUSION: 131I-mIBG therapy with 666 MBq/kg followed by single HDC and autologous or allogeneic SCT is safe and efficacious in patients with high-risk neuroblastoma and has no DLT. TRIAL REGISTRATION NUMBER: jRCTs041180030. NAME OF REGISTRY: Feasibility of high-dose iodine-131-meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and haematopoietic stem cell transplantation (High-dose iodine-131-meta-iodobenzylguanidine therapy for high-risk neuroblastoma). URL OF REGISTRY: https://jrct.niph.go.jp/en-latest-detail/jRCTs041180030 . DATE OF ENROLMENT OF THE FIRST PARTICIPANT TO THE TRIAL: 12/01/2018.
PURPOSE: Paediatric high-risk neuroblastoma has poor prognosis despite modern multimodality therapy. This phase I/II study aimed to determine the safety, dose-limiting toxicity (DLT), and efficacy of high-dose 131I-meta-iodobenzylguanidine (131I-mIBG) therapy combined with single high-dose chemotherapy (HDC) and haematopoietic stem cell transplantation (HSCT) in high-risk neuroblastoma in Japan. METHODS: Patients received 666 MBq/kg of 131I-mIBG and single HDC and HSCT from autologous or allogeneic stem cell sources. The primary endpoint was DLT defined as adverse events associated with 131I-mIBG treatment posing a significant obstacle to subsequent HDC. The secondary endpoints were adverse events/reactions, haematopoietic stem cell engraftment and responses according to the Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) and 123I-mIBG scintigraphy. Response was evaluated after engraftment. RESULTS: We enrolled eight patients with high-risk neuroblastoma (six females; six newly diagnosed and two relapsed high-risk neuroblastoma; median age, 4 years; range, 1-10 years). Although all patients had adverse events/reactions after high-dose 131I-mIBG therapy, we found no DLT. Adverse events and reactions were observed in 100% and 25% patients during single HDC and 100% and 12.5% patients during HSCT, respectively. No Grade 4 complications except myelosuppression occurred during single HDC and HSCT. The response rate according to RECIST 1.1 was observed in 87.5% (7/8) in stable disease and 12.5% (1/8) were not evaluated. Scintigraphic response occurred in 62.5% (5/8) and 37.5% (3/8) patients in complete response and stable disease, respectively. CONCLUSION: 131I-mIBG therapy with 666 MBq/kg followed by single HDC and autologous or allogeneic SCT is safe and efficacious in patients with high-risk neuroblastoma and has no DLT. TRIAL REGISTRATION NUMBER: jRCTs041180030. NAME OF REGISTRY: Feasibility of high-dose iodine-131-meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and haematopoietic stem cell transplantation (High-dose iodine-131-meta-iodobenzylguanidine therapy for high-risk neuroblastoma). URL OF REGISTRY: https://jrct.niph.go.jp/en-latest-detail/jRCTs041180030 . DATE OF ENROLMENT OF THE FIRST PARTICIPANT TO THE TRIAL: 12/01/2018.
Authors: Richard Li; Alexei Polishchuk; Steven DuBois; Randall Hawkins; Stephanie W Lee; Rochelle Bagatell; Suzanne Shusterman; Christine Hill-Kayser; Hasan Al-Sayegh; Lisa Diller; Daphne A Haas-Kogan; Katherine K Matthay; Wendy B London; Karen J Marcus Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-08 Impact factor: 7.038
Authors: Wendy B London; Victoria Castel; Tom Monclair; Peter F Ambros; Andrew D J Pearson; Susan L Cohn; Frank Berthold; Akira Nakagawara; Ruth L Ladenstein; Tomoko Iehara; Katherine K Matthay Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Katherine K Matthay; Jessica C Tan; Judith G Villablanca; Gregory A Yanik; Janet Veatch; Benjamin Franc; Eilish Twomey; Biljana Horn; C Patrick Reynolds; Susan Groshen; Robert C Seeger; John M Maris Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: K K Matthay; K DeSantes; B Hasegawa; J Huberty; R S Hattner; A Ablin; C P Reynolds; R C Seeger; V K Weinberg; D Price Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Katherine K Matthay; Brian Weiss; Judith G Villablanca; John M Maris; Gregory A Yanik; Steven G Dubois; James Stubbs; Susan Groshen; Denice Tsao-Wei; Randall Hawkins; Hollie Jackson; Fariba Goodarzian; Heike Daldrup-Link; Ashok Panigrahy; Alexander Towbin; Hiroyuki Shimada; John Barrett; Norman Lafrance; John Babich Journal: J Nucl Med Date: 2012-06-14 Impact factor: 10.057
Authors: Katherine K Matthay; Gregory Yanik; Julia Messina; Alekist Quach; John Huberty; Su-Chun Cheng; Janet Veatch; Robert Goldsby; Patricia Brophy; Leslie S Kersun; Randall A Hawkins; John M Maris Journal: J Clin Oncol Date: 2007-03-20 Impact factor: 44.544
Authors: S G DuBois; S Allen; M Bent; J F Hilton; F Hollinger; R Hawkins; J Courtier; Y P Mosse; K K Matthay Journal: Br J Cancer Date: 2015-01-20 Impact factor: 7.640